Table 6.
Multivariate analysis of LR, RR, and DM of young breast cancer patients
| Characteristics | LR | RR | DM | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Tumor size | < 0.01 | 0.11 | 0.01 | |||
| T1 | 1.0 | 1.0 | 1.0 | |||
| T2 | 0.5 (0.2–1.0) | 0.05 | 0.6 (0.3–1.4) | 0.24 | 1.4 (0.9–2.3) | 0.16 |
| T3 | 1.7 (0.6– 4.8) | 0.33 | 1.2 (0.5–2.9) | 0.74 | 1.8 (1.0–3.2) | 0.04 |
| T4 | 6.5 (1.2–36.9) | 0.03 | 4.2 (1.0–17.2) | 0.05 | 5.4 (2.0–14.0) | < 0.01 |
| Stage | 0.24 | 0.09 | 0.57 | |||
| I | 1.0 | 1.0 | 1.0 | |||
| II a | 1.7 (0.7–4.2) | 0.22 | 0.5 (0.2–1.6) | 0.26 | 1.4 (0.7–2.8) | 0.28 |
| II b | 2.1 (0.6–7.8) | 0.25 | 2.2 (0.6–8.8) | 0.25 | 1.3 (0.5–3.4) | 0.53 |
| III a | 0.7 (0.2–3.5) | 0.69 | 0.9 (0.2–4.4) | 0.90 | 2.1 (0.8–5.8) | 0.15 |
| III b | 0.9 (0.1–9.0) | 0.96 | 0.3 (0.0–4.8) | 0.43 | 1.2 (0.3–4.9) | 0.81 |
| III c | 0.5 (0.1–3.6) | 0.53 | 0.2 (0.0–1.5) | 0.11 | 4.2 (1.0–17.8) | 0.05 |
| LN metastasis | 0.06 | 0.02 | 0.59 | |||
| N0 | 1.0 | 1.0 | 1.0 | |||
| N1 | 2.0 (1.0–4.0) | 0.05 | 1.6 (0.6–4.1) | 0.32 | 1.5 (0.9–2.6) | 0.14 |
| N2 | 1.01 (0.3–3.5) | 0.93 | 7.1 (1.7–29.2) | < 0.01 | 1.3 (0.6–2.9) | 0.50 |
| N3 | 6.9 (1.4–35.0) | 0.02 | 34.7 (4.0–304.1) | < 0.01 | 1.3 (0.3–4.7) | 0.73 |
| Final surgery | – | – | 0.14 | |||
| Mastectomy | – | – | 1.0 | |||
| BCS | – | – | – | – | 0.7 (0.4–1.1) | 0.14 |
| ER status | 0.70 | – | – | |||
| Positive | 1.0 | – | – | |||
| Negative | 1.5 (0.6–3.9) | 0.40 | – | – | – | – |
| PR status | 0.54 | – | – | |||
| Positive | 1.0 | – | – | |||
| Negative | 1.5 (0.6–3.6) | 0.41 | – | – | – | – |
| HER2 status | 0.92 | – | – | |||
| Positive | 1.0 | – | – | |||
| Negative | 0.0 (0.0–NA) | 0.92 | – | – | – | – |
| MS | 0.49 | – | 0.01 | |||
| HR+/HER2− | 1.0 | – | 1.0 | |||
| HR+/HER2+ | 0.0 (0.0–NA) | 0.92 | – | – | 1.4 (0.9–2.1) | 0.15 |
| HR−/HER2+ | 0.0 (0.0–NA) | 0.92 | – | – | 2.5 (1.5–4.4) | < 0.01 |
| HR−/HER2− | 0.3 (0.1–1.2) | 0.10 | – | – | 1.9 (1.1–3.2) | 0.02 |
| NACT | 0.57 | 0.11 | 0.04 | |||
| No | 1.0 | 1.0 | 1.0 | |||
| Yes | 1.2 (0.7–2.2) | 0.57 | 1.6 (0.9–3.0) | 0.11 | 1.4 (1.0–2.0) | 0.04 |
| Radiotherapy | – | 0.10 | 0.64 | |||
| No | – | 1.0 | 1.0 | |||
| Yes | – | – | 0.5 (0.2–1.1) | 0.09 | 1.2 (0.7–2.0) | 0.41 |
| ET | 0.07 | – | – | |||
| No | 1.0 | – | – | |||
| Yes | 0.4 (0.2–1.0) | 0.04 | – | – | – | – |
| OFS | – | 0.03 | < 0.01 | |||
| No | – | 1.0 | 1.0 | |||
| Yes | – | – | 2.4 (1.2–4.6) | < 0.01 | 3.7 (2.3–5.8) | < 0.01 |
UA, univariate analysis; MA, multivariate analysis; HG, histological grade; MS, molecular subtype; NACT, neoadjuvant chemotherapy; ACT, adjuvant chemotherapy; ET, endocrine therapy; TT, trastuzumab therapy; NA, not arrived